Novo Nordisk on Tuesday received a broker downgrade, with the analysts arguing that its status as a duopoly in both diabetes and weight loss are under threat.
FlashNews:
Kimberly Gregory Turns a Lifetime Shaped by Addiction, Trauma, Grief, and Faith into a Message of Survival in Through Her Eyes
Ismael O. Cardona Blends Mystery, Supernatural Adventure, and the Power of True Friendship in The Painting
Roses are beautiful in appearance and character: Rose presents beauty in flowers, character, and family
Ruff Roofing Expands Texas Operations With Owens Corning Platinum Preferred Contractor Status
Solace Capital: Building a New Paradigm of Investment Research That Integrates Fundamentals and Quantitation with a Global Perspective
Timothy W. Hamilton’s Broken Lines Examines the Human Cost of a World Losing Its Connections
DEXORIN Observes Digital Asset Market Changes and Industry Trends
Euro slides to 17-month low against dollar
Spanish PM Sánchez seeks political lifeline in snap election
Brazil’s markets surge as investors bet on Bolsonaro win
Yemen launches push to retake territory captured by Houthis
US ‘monitoring’ situation around suspected case of plague in Russia
Georgina Hayden’s quick and easy recipe for corn gado gado | Quick and easy
Wyndham Hosts Hospitality Leaders at FHS World Dubai 2026 Cocktail Reception
What to do if you missed out on Glastonbury tickets
Indian singer Anuv Jain on finding success without the Bollywood boost
Best Power Banks (2026): My Picks After Testing Over 100
CMEx to honor Caribbean tourism leader Josef Forstmayr
Withings BodyScan 2 Review: Worth Its Weight
Home » Ozempic maker Novo Nordisk gets another downgrade. The end’s in sight for its duopoly status, says TD Cowen.